Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With <i>ERBB2</i> Amplification or <i>ERBB2/3</i> Mutations: Results From the TAPUR Study.

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 10; 6:e2200306.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Colorectal Neoplasms
Humans
Mutation
Receptor, ErbB-2
Trastuzumab

authors with profiles

Richard Schilsky